Hepatitis C is rising in the United States, with rural communities and people who inject drugs disproportionately affected. The piece argues that rural hepatitis C virus (HCV) risk is not just an individual behavior issue, but a product of overlapping structural barriers, including economic inequality, stigma, punitive drug policies, limited transportation, under-resourced healthcare systems, and reduced access to prevention and treatment. These challenges can make it harder for people to seek care, start treatment, and achieve cure, especially when distrust of traditional healthcare settings is high.

The author calls for multilevel, rural-specific interventions that address the root causes of HCV risk while expanding access to nonjudgmental, practical care. Promising models include mobile and telehealth-based HCV treatment combined with harm reduction services, which have shown improved treatment initiation and completion among rural people who inject drugs. The bottom line: reducing rural HCV transmission will require healthcare providers, policymakers, and researchers to work together on solutions that meet people where they are-clinically, geographically, and socially.

Reference: Bailey A, Tarplin S, Kang AW. Untangling the web of hepatitis C risk in rural communities. J Gen Intern Med. 2026 Feb;41:859-860. doi: 10.1007/s11606-025-09913-9. Epub 2025 Oct 14. PMID: 41085963.

This review explains that the hepatitis C virus (HCV) remains a major global health problem despite major progress in diagnosis and treatment. It traces HCV from its discovery as “non-A, non-B” hepatitis to today’s understanding of it as a highly diverse RNA virus with at least seven major genotypes, each with differences in geography, treatment response, and disease patterns. The review outlines how HCV infects the liver, evades immune defenses, and often becomes chronic, which can lead to fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma. It also emphasizes that HCV is transmitted mainly through blood exposure, including unsafe injections, drug injection, transfusions of unscreened blood, and less commonly sexual or mother-to-child transmission, with an estimated 50 million people infected globally and about 242,000 deaths in 2022.

The review also highlights how HCV care has been transformed by direct-acting antivirals, which can cure more than 95% of patients with shorter, better-tolerated regimens than older interferon-based therapy. At the same time, it stresses that major challenges remain, especially drug resistance, limited global access to treatment, and the continued lack of an effective vaccine. Prevention still depends heavily on universal screening, harm-reduction efforts, infection-control practices, and treatment as prevention. Elimination by 2030 will require broader diagnostic access, more affordable treatment, stronger adherence and resistance monitoring, and continued research into vaccines and new therapies.

Reference: Sallam M, Khalil R. Contemporary insights into hepatitis C virus: a comprehensive review. Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035. PMID: 38930417.

This randomized trial evaluated whether ultrashort courses of direct-acting antiviral (DAA) therapy could help treat adults with chronic hepatitis C virus (HCV) who may struggle to complete standard 8-12 week regimens. Participants with mild liver disease were assigned to either a fixed 8-week DAA course or a variable ultrashort course based largely on baseline viral load, with some also receiving ribavirin. After first-line treatment alone, the fixed-duration group had much higher cure rates than the ultrashort group, but the revised ultrashort approach performed better than the initial version, suggesting that even a modest increase in treatment duration can substantially improve sustained virologic response.

Importantly, all evaluable participants ultimately achieved cure after retreatment, meaning the ultrashort strategy did not appear to compromise the ability to successfully treat patients who failed first-line therapy. Ribavirin did not significantly improve initial cure rates, but it was associated with lower emergence of resistance among those who failed treatment. The authors conclude that ultrashort therapy is not ready for routine use in stable patients who can complete standard therapy, but it may have future value in supervised or hard-to-reach settings where completing a full treatment course is unlikely.

Reference: Reference: Cooke GS, Pett S, McCabe L, et al. Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C. Wellcome Open Res. 2021;6:93. doi: 10.12688/wellcomeopenres.16594.2. Published 2021 Jul 29.